GH Research Reports 100% Remission in Phase 2a Postpartum Depression Trial for GH001
GHRS has more than doubled off its 52-week low of $10.96.
Summary
GH Research published full Phase 2a results for GH001 in postpartum depression, showing 100% remission and a favorable safety profile, alongside announcing upcoming presentations for its TRD data.
Key Events · Product Development and Regulatory · GHRS
-
Exceptional Phase 2a PPD Results Published
Full results for GH001 in postpartum depression (PPD) show a mean MADRS reduction of -35.4 points and 100% of patients achieving remission (MADRS total score ≤10) within two hours of dosing, sustained through Day 8.
-
Favorable Safety and Breastfeeding Profile
The Phase 2a trial reported no serious adverse events, with all treatment-emergent adverse events being mild or moderate. An analysis of breast milk supports a treatment strategy with only a brief interruption of breastfeeding.
-
Upcoming TRD Data Presentations
Two featured communications have been accepted for oral presentation at the 37th World Congress of Neuropsychopharmacology (CINP 2026) to present data from the Phase 2b GH001-TRD-201 trial in treatment-resistant depression (TRD).
Analysis · GHRS · Life Sciences
GH Research announced the publication of highly positive full Phase 2a trial results for GH001 in postpartum depression (PPD). All 10 patients achieved remission within hours, sustained through Day 8, with a favorable safety profile. This strong efficacy data significantly de-risks the PPD program and supports further investigation, potentially expanding the market opportunity for GH001 beyond treatment-resistant depression.
At the time of this filing, GHRS was trading at $24.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $10.96 to $25.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.